"10.1371_journal.pone.0094462","plos one","2014-04-14T00:00:00Z","Robert S Wallis; Rodney Dawson; Sven O Friedrich; Amour Venter; Darcy Paige; Tong Zhu; Annette Silvia; Jason Gobey; Craig Ellery; Yao Zhang; Kathleen Eisenach; Paul Miller; Andreas H Diacon","Formerly Pfizer Inc, Groton, Connecticut, United States of America; University of Cape Town, Cape Town, South Africa; Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; Medical Research Council Centre for Molecular and Cellular Biology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; Pfizer, Groton, Connecticut, United States of America; University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America","Conceived and designed the experiments: RSW RD AV SF DP TZ AS JG CE YZ KE PM AHD. Performed the experiments: RD AV SF AHD. Analyzed the data: YZ TZ RSW. Contributed reagents/materials/analysis tools: RSW. Wrote the paper: RSW RD AV SF DP TZ AS JG CE YZ KE PM AHD.","The authors have read the journals policy and have the following conflicts: RSW, DP, TZ, AS, JG, CE, YZ and PM are/were Pfizer employees, and/or shareholders at the time the study was conducted, whose company funded this study. KE of the University of Arkansas was a paid consultant to Pfizer Inc in regards to the study design. Rights to sutezolid were acquired by Sequella, Inc. in 2013. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","04","Robert S Wallis","RSW",13,TRUE,13,4,3,13,TRUE,TRUE,FALSE,0,NA,FALSE
